Jonathan W Riess

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
    Jonathan W Riess
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
    Cancer Invest 30:231-5. 2012
  2. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    J Natl Compr Canc Netw 11:389-94. 2013
  3. doi request reprint Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era
    Jonathan W Riess
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA Department of Internal Medicine, University of California Davis School of Medicine Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA Electronic address
    Clin Lung Cancer 15:202-6. 2014
  4. doi request reprint Diffuse high intensity PD-L1 staining in thymic epithelial tumors
    Sukhmani K Padda
    Division of Oncology, Department of Internal Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA Department of Pathology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA and Department of Health and Research Policy, Stanford University School of Medicine, Stanford, CA
    J Thorac Oncol 10:500-8. 2015
  5. ncbi request reprint GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray
    Jonathan W Riess
    Department of Medicine, Division of Hematology Oncology, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, CA, U S A Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, U S A
    Anticancer Res 35:669-76. 2015
  6. ncbi request reprint Metastatic non-small cell lung cancer management: novel targets and recent clinical advances
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Adv Hematol Oncol 10:226-34. 2012
  7. doi request reprint ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
    Millie Das
    Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
    Lung Cancer 77:421-6. 2012
  8. doi request reprint Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
    Immunopharmacol Immunotoxicol 36:182-6. 2014

Collaborators

Detail Information

Publications8

  1. doi request reprint Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
    Jonathan W Riess
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
    Cancer Invest 30:231-5. 2012
    ..268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients...
  2. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    J Natl Compr Canc Netw 11:389-94. 2013
    ....
  3. doi request reprint Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era
    Jonathan W Riess
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA Department of Internal Medicine, University of California Davis School of Medicine Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA Electronic address
    Clin Lung Cancer 15:202-6. 2014
    ..Leptomeningeal carcinomatosis (LM) is a severe complication of non-small-cell lung cancer (NSCLC) historically associated with poor prognosis. New chemotherapeutic and targeted treatments could potentially affect the natural history of LM...
  4. doi request reprint Diffuse high intensity PD-L1 staining in thymic epithelial tumors
    Sukhmani K Padda
    Division of Oncology, Department of Internal Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA Department of Pathology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA and Department of Health and Research Policy, Stanford University School of Medicine, Stanford, CA
    J Thorac Oncol 10:500-8. 2015
    ..PD-L1 protein expression by immunohistochemistry is emerging as a predictive biomarker of response to these therapies. Here, we examine PD-L1 expression in a thymic epithelial tumor (TET) tissue microarray (TMA)...
  5. ncbi request reprint GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray
    Jonathan W Riess
    Department of Medicine, Division of Hematology Oncology, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, CA, U S A Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, U S A
    Anticancer Res 35:669-76. 2015
    ....
  6. ncbi request reprint Metastatic non-small cell lung cancer management: novel targets and recent clinical advances
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Adv Hematol Oncol 10:226-34. 2012
    ..This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment...
  7. doi request reprint ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
    Millie Das
    Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
    Lung Cancer 77:421-6. 2012
    ....
  8. doi request reprint Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
    Immunopharmacol Immunotoxicol 36:182-6. 2014
    ....